Nasdaq: RGLS

Regulus Therapeutics Inc.

Regulus was formed in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus benefits substantially from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. Regulus has access to over 850 patents and patent applications pertaining to oligonucleotide technologies useful for targeting microRNA therapeutics, and over 200 patents and patent applications directed to microRNA specific technologies.